Research programme: XD 4241 - Xcellsyz
Alternative Names: XD4000 series - XcellsyzLatest Information Update: 17 Apr 2007
At a glance
- Originator Xcellsyz
- Class Antihyperglycaemics
- Mechanism of Action Glycogen synthase kinase 3 inhibitors; Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Cancer; Cardiovascular disorders; Diabetes mellitus
Most Recent Events
- 17 Apr 2007 Discontinued - Preclinical for Alzheimer's disease in United Kingdom (unspecified route)
- 17 Apr 2007 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 17 Apr 2007 Discontinued - Preclinical for Cardiovascular disorders in United Kingdom (unspecified route)